Work Here?
About Travere Therapeutics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
San Diego, California
Founded
2008
Overview
Travere Therapeutics focuses on creating therapies for individuals affected by rare diseases. The company identifies specific rare conditions and develops treatments tailored to those needs. Their approach involves extensive research and collaboration with the medical community to ensure that the therapies are effective and safe for patients. Unlike many pharmaceutical companies that may prioritize more common diseases, Travere is dedicated to addressing the unique challenges faced by those with rare conditions. The ultimate goal of Travere Therapeutics is to improve the quality of life for patients living with rare diseases by providing them with effective treatment options.
Simplify's Take
What believers are saying
- Raised $144 million in 2024 to support clinical development and strategic initiatives.
- Integration of digital health technologies can improve clinical trial processes.
- Expansion of telemedicine services facilitates better patient monitoring and follow-up care.
What critics are saying
- Increased competition in the IgAN treatment market from Calliditas Therapeutics.
- Potential talent drain as key personnel leave for other companies.
- Market volatility in biotech sector could impact stock performance and funding.
What makes Travere Therapeutics unique
- Focus on rare diseases sets Travere apart in the biopharmaceutical industry.
- Strong collaboration with patient advocacy groups enhances drug development processes.
- Commitment to personalized medicine increases treatment efficacy for rare diseases.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$3.9M
Below
Industry Average
Funded Over
3 Rounds
Benefits
Health Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Paid Vacation
Wellness Program
Company Equity
Company News
The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.
The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.
Travere Therapeutics announced on November 12, 2024, that it raised approximately $144 million through a public offering, selling 8,984,375 shares at $16 each, including 1,171,875 shares from underwriters' overallotment options. The funds will support clinical development, operations, and strategic initiatives. This move comes amid challenging biotech market conditions and aims to address unmet medical needs in rare diseases. Travere also shared updates on its talent acquisition strategy.
The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts.
Travere Therapeutics (Nasdaq: TVTX) has announced plans for an underwritten public offering of its common stock.
Travere Therapeutics is Hiring for 28 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Travere Therapeutics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
San Diego, California
Founded
2008
Travere Therapeutics is Hiring for 28 Jobs on Simplify!
Find jobs on Simplify and start your career today